Natural Product-Derived Small Molecule Activators of Hypoxia-Inducible Factor-1 (HIF-1)

Author(s): Dale G. Nagle, Yu-Dong Zhou.

Journal Name: Current Pharmaceutical Design

Volume 12 , Issue 21 , 2006

Become EABM
Become Reviewer

Abstract:

Hypoxia-inducible factor-1 (HIF-1) is a key mediator of oxygen homeostasis that was first identified as a transcription factor that is induced and activated by decreased oxygen tension. Upon activation, HIF-1 upregulates the transcription of genes that promote adaptation and survival under hypoxic conditions. HIF-1 is a heterodimer composed of an oxygen-regulated subunit known as HIF-1α and a constitutively expressed HIF-1β subunit. In general, the availability and activity of the HIF-1α subunit determines the activity of HIF-1. Subsequent studies have revealed that HIF-1 is also activated by environmental and physiological stimuli that range from iron chelators to hormones. Preclinical studies suggest that HIF-1 activation may be a valuable therapeutic approach to treat tissue ischemia and other ischemia/hypoxia-related disorders. The focus of this review is natural product-derived small molecule HIF-1 activators. Natural products, relatively low molecular weight organic compounds produced by plants, animals, and microbes, have been and continue to be a major source of new drugs and molecular probes. The majority of known natural product-derived HIF-1 activators were discovered through the pharmacological evaluation of specifically selected individual compounds. On the other hand, the combination of natural products chemistry with appropriate high-throughput screening bioassays may yield novel natural product-derived HIF-1 activators. Potent natural product-derived HIF-1 activators that exhibit a low level of toxicity and side effects hold promise as new treatment options for diseases such as myocardial and peripheral ischemia, and as chemopreventative agents that could be used to reduce the level of ischemia/reperfusion injury following heart attack and stroke.

Keywords: HIF-1, Natural Product, Tissue Ischemia, herapeutic Angiogenesis, Molecular-Target, Small Molecule Activator, Chemoprevention, Ischemia/Reperfusion Injury

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 12
ISSUE: 21
Year: 2006
Page: [2673 - 2688]
Pages: 16
DOI: 10.2174/138161206777698783
Price: $58

Article Metrics

PDF: 5